Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439752 | 0.88 | L3MBTL1 (0.49) | L3MBTL1FDPSTSHRDAONOS1 | |
| SCHEMBL438475 | 0.86 | L3MBTL1 (0.48) | L3MBTL1FDPSTSHRDAONOS1 | |
| SCHEMBL21996528 | 0.85 | TSHR (0.44) | L3MBTL1FDPSTSHRDAONOS1 | |
| SCHEMBL31581978 | 0.85 | TSHR (0.44) | L3MBTL1FDPSTSHRDAONOS1 | |
| SCHEMBL10192257 | 0.83 | FDPS (0.38) | L3MBTL1FDPSTSHRDAONOS1 | |
| SCHEMBL10153324 | 0.80 | FDPS (0.36) | L3MBTL1FDPSTSHRDAONOS1 | |
| SCHEMBL19222041 | 0.80 | LMNA (0.36) | L3MBTL1FDPSTSHRDAOLMNA | |
| SCHEMBL28810777 | 0.79 | PSEN1 (0.36) | L3MBTL1FDPSTSHRDAOLMNA | |
| SCHEMBL5713341 | 0.78 | DAO (0.50) | FDPSTSHRDAONOS1LMNA | |
| SCHEMBL1075475 | 0.78 | FDPS (0.37) | L3MBTL1FDPSTSHRDAOLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101668425-A | Tri-aryl/heteroaroaromatic cannabinoids and use thereof | UNIV TENNESSEE RES FOUNDATION | 2010-03-10 | — | — | CN | claimed |
| EP-2131655-A2 | TRI-ARYL/HETEROAROMATIC CANNABINOIDS AND USE THEREOF | The University of Tennessee Research Foundation (US) | 2009-12-16 | — | — | EP | claimed |
| WO-2008109027-A2 | TRI-ARYL/HETEROAROAROMATIC CANNABINOIDS AND USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, THE (US) | 2008-09-12 | — | — | WO | claimed |
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-07-18 | — | — | US | disclosed |
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-07-18 | — | — | US | disclosed |
| WO-2024112830-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| WO-2024003535-A2 | COMPOUNDS | UNIVERSITY OF DUNDEE (GB) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023212019-A1 | PYRIMIDINONE-CONTAINING 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| US-11771715-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11771715-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11766449-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-07-17 | — | — | US | disclosed |
| US-7393873-B2 | Arylsulfonamide derivatives | MERCK & CO., INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-20080103130-A1 | 7-hydroxy-6-{[1-methyl-3-(1,3-thiazol-5-yl)propyl]amino}-4,5,6,7-tetrahydroimidazo[4,5,1-jk][1]benzazepin-2(1H)-one; agonists at the beta-2 adrenoceptor; feed additives for livestock animals; improving meat yield or meat quality | PFIZER LIMITED (GB) | 2008-05-01 | — | — | US | disclosed |
| US-7335632-B2 | Beta-secretase inhibitors and methods of use thereof | COMENTIS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20060234944-A1 | Beta-secretase inhibitors and methods of use | OKLAHOMA MEDICAL RESEACH FOUNDATION (US) | 2006-10-19 | — | — | US | disclosed |
| US-20050239684-A1 | Compounds which inhibit beta-secretase activity and methods of use thereof | ZAPAQ, INC. (US) | 2005-10-27 | — | — | US | disclosed |
| EP-1448218-A2 | BETA-SECRETASE INHIBITORS AND METHODS OF USE | Oklahoma Medical Research Foundation (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20040121947-A1 | Compounds which inhibit beta-secretase activity and methods of use thereof | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2004-06-24 | — | — | US | disclosed |
| WO-2003039454-A2 | BETA-SECRETASE INHIBITORS AND METHODS OF USE | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060234944-A1 | Beta-secretase inhibitors and methods of use | BACE2, BACE1, PSEN2 | L3MBTL1 2703/4885FDPS 2402/4885TSHR 4773/4885 |
| US-11771715-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | L3MBTL1 544/4885FDPS 2341/4885TSHR 1491/4885 |
| US-20050239684-A1 | Compounds which inhibit beta-secretase activity and methods of use thereof | BACE1, BACE2, APP | L3MBTL1 1341/4885FDPS 1912/4885TSHR 4830/4885 |
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | CHI3L2, CHI3L1, FGF2 | L3MBTL1 2294/4885FDPS 4279/4885TSHR 2669/4885 |
| US-20080103130-A1 | 7-hydroxy-6-{[1-methyl-3-(1,3-thiazol-5-yl)propyl]amino}-4,5,6,7-tetrahydroimidazo[4,5,1-jk][1]benzazepin-2(1H)-one; agonists at the beta-2 adrenoceptor; feed additives for livestock animals; improving meat yield or meat quality | ADRB2, ADRB1, ADRA2C | L3MBTL1 3143/4885FDPS 4292/4885TSHR 783/4885 |
| US-20080171769-A1 | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | MALT1, TPMT, TSLP | L3MBTL1 4527/4885FDPS 1132/4885TSHR 3298/4885 |
| US-20040121947-A1 | Compounds which inhibit beta-secretase activity and methods of use thereof | BACE2, BACE1, PSEN2 | L3MBTL1 2659/4885FDPS 1860/4885TSHR 4797/4885 |
| US-11766449-B2 | Circular RNA compositions and methods | RTCB, RNGTT, HNRNPAB | L3MBTL1 544/4885FDPS 2327/4885TSHR 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.